- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Type1diabetes, Diabetes Mellitus
- Interventions
- YG1699, Dapagliflozin
- Drug
- Lead sponsor
- Youngene Therapeutics Inc., Ltd.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chula Vista, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 187
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Genetic Polymorphisms, Heart Failure
- Interventions
- SGLT2 inhibitors (Dapagliflozin and Empagliflozin)
- Drug
- Lead sponsor
- October 6 University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Lupus Nephritis (LN)
- Interventions
- Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Atrial Fibrillation
- Interventions
- dapagliflozin, Placebo
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 3
- States / cities
- Portland, Maine • Detroit, Michigan • Rochester, New York
- Conditions
- Weight Loss
- Interventions
- Dapagliflozin, Placebo, Weight maintenance, Ad libitum dietary intake, Dietary restriction
- Drug · Behavioral
- Lead sponsor
- Christopher Bell
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Fort Collins, Colorado
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Williamsville, New York
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF)
- Interventions
- Dapagliflozin, Placebo
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 150 Years
- Enrollment
- 313 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 23
- States / cities
- Alexander City, Alabama • Fairhope, Alabama • Fort Payne, Alabama + 19 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo-matching dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 2,996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 164
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Dapagliflozin 5mg, Placebo Oral Tablet
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo for dapagliflozin
- Drug · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 815 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 47
- States / cities
- Concord, California • Fresno, California • Los Angeles, California + 40 more
- Conditions
- Acute Kidney Injury, Percutaneous Coronary Intervention
- Interventions
- Dapagliflozin 10mg Tab
- Drug
- Lead sponsor
- Albert Einstein Healthcare Network
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Dapagliflozin, Saxagliptin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 20
- States / cities
- Sacramento, California • New Haven, Connecticut • Hialeah, Florida + 12 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo, Hydrochlorothiazide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Anaheim, California • Lomita, California • Miami, Florida + 5 more
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Metformin, Placebo
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Chronic Kidney Disease
- Interventions
- Zibotentan (Treatment A), Dapagliflozin (Treatment A), Zibotentan/Dapagliflozin - Formulation 1 (Treatment B), Zibotentan/Dapagliflozin - Formulation 2 (Treatment C)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Prostate Cancer, Cancer of Prostate
- Interventions
- Dapagliflozin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 2 Diabetes Mellitus, Inadequate Glycaemic Control
- Interventions
- Dapagliflozin, Placebo for Dapagliflozin, Saxagliptin, Placebo for Saxagliptin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 905 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 48
- States / cities
- Saraland, Alabama • Fresno, California • Harbor City, California + 41 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer
- Interventions
- Dapagliflozin 10mg
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Cardiovascular Events, Type2 Diabetes, Renal Disease
- Interventions
- SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 781,430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Exenatide, Dapagliflozin, Exenatide and Dapagliflozin
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Dapagliflozin, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 16
- States / cities
- Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more
- Conditions
- Type 2 Diabetes
- Interventions
- Orforglipron, Dapagliflozin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 962 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 19
- States / cities
- Canoga Park, California • Long Beach, California • Los Alamitos, California + 16 more